H

Hana Pharm Co Ltd
KRX:293480

Watchlist Manager
Hana Pharm Co Ltd
KRX:293480
Watchlist
Price: 11 010 KRW 0.82% Market Closed
Market Cap: 190.5B KRW
Have any thoughts about
Hana Pharm Co Ltd?
Write Note

Hana Pharm Co Ltd
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Hana Pharm Co Ltd
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
H
Hana Pharm Co Ltd
KRX:293480
Cash from Operating Activities
â‚©25.3B
CAGR 3-Years
24%
CAGR 5-Years
-4%
CAGR 10-Years
N/A
Yuhan Corp
KRX:000100
Cash from Operating Activities
â‚©59.7B
CAGR 3-Years
-2%
CAGR 5-Years
-4%
CAGR 10-Years
-3%
SK Biopharmaceuticals Co Ltd
KRX:326030
Cash from Operating Activities
-â‚©94.2B
CAGR 3-Years
24%
CAGR 5-Years
8%
CAGR 10-Years
N/A
Hanmi Pharm Co Ltd
KRX:128940
Cash from Operating Activities
â‚©222.9B
CAGR 3-Years
-1%
CAGR 5-Years
34%
CAGR 10-Years
N/A
S
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Cash from Operating Activities
â‚©38.4B
CAGR 3-Years
N/A
CAGR 5-Years
3%
CAGR 10-Years
9%
C
Celltrion Pharm Inc
KOSDAQ:068760
Cash from Operating Activities
â‚©55.9B
CAGR 3-Years
-10%
CAGR 5-Years
12%
CAGR 10-Years
N/A
No Stocks Found

Hana Pharm Co Ltd
Glance View

Market Cap
190.5B KRW
Industry
Pharmaceuticals

Hana Pharm Co., Ltd. engages in the research, development, and manufacture of pharmaceutical products. The company is headquartered in Hwaseong, Gyeonggi-Do and currently employs 657 full-time employees. The company went IPO on 2018-10-02. The company’s main products include cardiovascular drugs involves hypertension and hyperlipidemia medicines, as well as blood circulation improvement drugs; analgesics for severe pain and anesthetics for surgery and sedation; as well as gastrointestinal drugs such as peptic ulcer treatment and antispasmodics. The firm also provides antibiotics, dermatology analgesics, antipyretics and anti-inflammatory drugs.

Intrinsic Value
18 041.77 KRW
Undervaluation 39%
Intrinsic Value
Price
H

See Also

What is Hana Pharm Co Ltd's Cash from Operating Activities?
Cash from Operating Activities
25.3B KRW

Based on the financial report for Sep 30, 2024, Hana Pharm Co Ltd's Cash from Operating Activities amounts to 25.3B KRW.

What is Hana Pharm Co Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-4%

Over the last year, the Cash from Operating Activities growth was 20%. The average annual Cash from Operating Activities growth rates for Hana Pharm Co Ltd have been 24% over the past three years , -4% over the past five years .

Back to Top